Search for content, post, videos

Interview: Jens Bjørheim, Chief Medical Officer, Ultimovacs

The company’s universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab, has recently demonstrated a 60% objective response rate in metastatic malignant melanoma. Nordic Life Science asked the Chief Medical Officer (CMO) of Ultimovacs, Jens Bjørheim, about the n
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.